Indeno[1,2-b]pyrazin-2,3-diones: A new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity

Journal of Medicinal Chemistry

Volumn 43, Issue 12, 2000, Pages 2371-2381

  Jimonet, Patrick ^a   Ribeill, Yves ^a,b   Bohme, Georg Andrees ^a   Boireau, Alain ^a   Chevé, Michel ^a   Damour, Dominique ^a   Doble, Adam ^a   Genevois Borella, Arielle ^a   Herman, Frédéric ^a   Imperato, Assunta ^a   Le Guern, Sylvain ^a   Manfré, Franco ^a   Pratt, Jeremy ^a   Randle, John C R ^a,c   Stutzmann, Jean Marie ^a   Mignani, Serge ^a  

^a SANOFI   (France)

^b Aventis CropScience   (United States)

^c VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(8 CHLORO 5 METHYL 2,3 DIOXO 1,4 DIHYDRO 5H INDENO[1,2 B]PYRAZIN 5 YL)ACETIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CHLORINE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RPR 118723; SODIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CONVULSION; DOSE RESPONSE; DRUG BINDING; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; RAT;

ANIMALS; ANTICONVULSANTS; CELLS, CULTURED; CEREBELLUM; CEREBRAL CORTEX; EXCITATORY AMINO ACID ANTAGONISTS; LONG-TERM POTENTIATION; MICE; NEURONS; PATCH-CLAMP TECHNIQUES; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; STEREOISOMERISM;

EID: 0033947294     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990957g     Document Type: Article

References (30)

1. (a) Meldrum, B.; Garthwaite, J. Excitatory Amino Acid Neurotoxicity and Neurodegenerative Diseases. Trends Pharmacol. 1990, 11, 379-387.
2. (b) Rothman, S. M.; Olney, J. W. Excitotoxicity and the NMDA Receptor-Still Lethal After Eight Years. Trends Neurosci. 1995, 18, 57-58.
3. (a) McCulloch, J. Excitatory Amino Acid Antagonists and their Potential for the Treatment of Ischemic Brain Damage in Man. Br. J. Clin. Pharmacol. 1992, 34, 106-114.
4. (b) Muir, K. W.; Lees, K. R. Clinical Experience with Excitatory Amino Acid Antagonist Drugs. Stroke 1995, 26, 503-513.
5. (a) Tricklebank, M. D.; Singh, L.; Oles, R. J.; Preston, C.; Iversen, S. D. The Behavioural Effects of MK-801; A Comparison with Compounds Acting Non-Competitively and Competitively at the NMDA Receptor. Eur. J. Pharmacol. 1989, 167, 127-135.
6. (b) Koek, W.; Colpaert, F. C. Selective Blockade of N-Methyl-D-Aspartate (NMDA)-induced Convulsions by NMDA Antagonists and Putative Glycine Antagonists: Relationship with Phenylcyclidine-like Behavioral Effects. J. Pharmacol. Exp. Ther. 1990, 252, 349-357.
7. (a) Johnson, J. W.; Ascher, P. Glycine Potentiates the NMDA Receptor Response in Cultured Brain Mouse Neurones. Nature 1987, 325, 529-531.
8. (b) Kleckner, N. W.; Dingledine, R. Requirements for Glycine in Activation of NMDA Receptors Expressed in Xenopus Oocytes. Science 1988, 241, 835-837.
9. (a) Kemp, J. A.; Leeson, P. D. The Glycine Site of the NMDA Receptor-Five Years on. Trends Pharmacol. Sci. 1993, 14, 20-25.
10. (b) Kulagowski, J. J. Glycine-site NMDA Receptor Antagonists: an Update. Exp. Opin. Ther. Patents 1996, 6, 1069-1079 and references cited.
11. (c) Di Fabio R.; Capelli, A. M.; Conti, N.; Cugola, A.; Donati, D.; Feriani, A.; Gastaldi, P.; Gaviraghi, G.; Hewkin, C. T.; Micheli, F.; Missio, A.; Mugnaini, M.; Pecunioso, A.; Quaglia, A. M.; Ratti, E.; Rossi, L.; Tedesco, G.; Trist, D. G.; Reggiani, A. Substituted Indole-2-carboxylates as in vivo Potent Antagonists Acting at the Strychnine-Insensitive Glycine Binding Site. J. Med. Chem. 1997, 40, 841-850.
12. (d) Carling, R. W.; Leeson, P. D.; Moore, K. W.; Moyes, C. R.; Duncton, M.; Hudson, M. L.; Baker, R.; Foster, A. C.; Grimwood, S.; Kemp, J. A.; Marshall, G. R.; Tricklebank, M. D.; Saywell, K. L. 4-Substituted-3-phenylquinolin-2(1H)-ones: Acidic and Nonacidic Glycine Site N-Methyl-D-aspartate Antagonists with in vivo Activity. J. Med. Chem. 1997, 40, 754-765.
13. (a) Keana, J. F. W.; Kher, S. N.; Xiong Cai, S.; Dinsmore, C. M.; Glenn, A. G.; Guastella, J.; Huang, J.-C.; Ilyin, V.; Lü, Y.; Mouser, P. L.; Woodward, R. M.; Weber, E. Synthesis and Structure-Activity Relationships of Substituted 1,4-Dihydroquinoxaline-2,3-diones: Antagonists of N-Methyl-D-Aspartate (NMDA) Receptor Glycine Sites and Non-NMDA Glutamate Receptors. J. Med. Chem. 1995, 38, 8, 4367-4379.
14. (b) Takano, K.; Tatlisumak, T.; Formato, J. E.; Carano, R. A. D.; Bergmann, A. G.; Pullan, L. M.; Bare, T. M.; Sotak, C. H.; Fisher, M. Glycine Site Antagonist Attenuates Infarct Size in Experimental Focal Ischemia. Stroke 1997, 28, 1255-1263.
15. (c) Di Fabio, R.; Cugola, A.; Donati, D.; Feriani, A.; Gaviraghi, G.; Ratti, E.; Trist, D. G.; Reggiani, A. Identification and Pharmacological Characterization of GV150526, a Novel Glycine Antagonist as a Potent Neuroprotective Agent. Drugs Future 1998, 23, 61-69.
16. (a) Jimonet, P.; Audiau, F.; Aloup, J. C.; Barreau, M.; Blanchard, J. C.; Böhme, A.; Boireau, A.; Chevé, M.; Damour, D.; Doble, A.; Lavayre, J.; Dutruc-Rosset, G.; Randle, J. C. R.; Rataud, J.; Stutzmann, J. M.; Mignani, S. Synthesis and SAR of 2H-1,2,4-Benzothiadiazine-1,1-dioxide-3-carboxylic acid Derivatives as Novel Potent Glycine Antagonists of the NMDA Receptor-Channel Complex. Bioorg. Med. Chem. Lett. 1994, 4, 2735-2740.
17. (b) Boireau, A.; Malgouris, C.; Burgevin, M. C.; Peny, C.; Durand, G.; Bordier, F.; Miquet, J. M.; Meunier, M.; Daniel, M.; Chevet, T.; Jimonet, P.; Mignani, S.; Blanchard, J. C.; Doble, A. Neuroprotective Effects of RPR 104632, a Novel Antagonist at the Glycine Site of the NMDA Receptor, in vitro. Eur. J. Pharmacol. 1996, 300, 237-246.
18. (c) Mignani, S.; Aloup, J. C.; Barreau, M.; Birraux, G.; Blanchard, J. C.; Bohme, A.; Boireau, A.; Damour, D.; Doble, A.; Jimonet, P.; Malgouris, C.; Mary, V.; Randle, J. C. R.; Rataud, J. and Stutzmann, J. M. 2H-3,4-Dihydro-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxylic acid Derivatives, a novel family of glycine antagonists of the NMDA receptor channel complex. Drugs Future 1995, 20, 1133-1143.
19. See ref 5b, pages 1073 and 1074, and references cited.
20. (a) Kulagowski, J. J.; Baker, R.; Curtis, N. R.; Leeson, P. D.; Mawer, I. M.; Moseley, A. M.; Ridgill, M. P.; Rowley, M.; Stansfield, I.; Foster, A. C.; Grimwood, S.; Hill, R. G.; Kemp, J. A.; Marshall, G. R.; Saywell, K. L.; Tricklebank, M. D. 3′-(Arylmethyl)- and 3′-(Aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor. J. Med. Chem. 1994, 37, 1402-1405.
21. (b) Maruoka, Y.; Ohno, Y.; Tanaka, H.; Yasuda, H.; Otani, K.; Tamamura, C.; Nakamura, M. Effects of the novel tricyclic quinoxalinedione derivatives, SM-18400 and its analogues, on N-methyl-D-aspartate (NMDA) receptor-mediated synaptic transmission in the isolated neonatal rat spinal cord in vitro. Jpn. J. Pharmacol. 1998, 76, 265-270.
22. 3H]Dichlorokynurenic acid. J. Pharm. Pharmacol. 1992, 44, 812-816.
23. (b) Honore, T.; Drejer, J. Chaotropic ions affect the conformation of quisqualate receptors in rat cortical membranes. J. Neurochem. 1988, 57, 457-461.
24. Swinyard, E. A.; Brown, W. C. and Goodman, L. S. Comparative Assays of Antiepileptic Drugs in Mice and Rats. J. Pharmacol. Exp. Ther. 1952, 106, 319-330.
25. Rowley, M.; Kulagowski, J. J.; Watt, A. P.; Rathbone, D.; Stevenson, G. I.; Carling, R. W.; Baker, R.; Marshall, G. R.; Kemp J. A.; Foster, A. C.; Grimwood, S.; Hargreaves, R.; Hurley, C.; Saywell, K. L.; Tricklebank, M. D.; Leeson, P. D. Effect of Plasma Protein Binding on in Vivo Activity and Brain Penetration of Glycine/NMDA Receptor Antagonists. J. Med. Chem. 1997, 40, 4053-4068.
26. Leeson, P. D.; Baker, R.; Carling, R. W.; Curtis, N. R.; Moore, K. W.; Williams, B. J.; Foster, A. C.; Donald, A. E.; Kemp, J. A.; Marshall, G. R. Kynurenic Acid Derivatives. Structure-Activity Relationships for Excitatory Amino Acid Antagonism and Identification of Potent and Selective Antagonists at the Glycine Site on the N-methyl-D-aspartate Receptor. J. Med. Chem. 1991, 34, 1243-1252.
27. Hardman, J. G.; Limbird, L. E.; Molinoff, P. B.; Ruddon, R. W.; Goodman-Gilman, A. Eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed.; McGraw-Hill: New York, 1996; pp 651-652.
28. Chakravarty, J.; Ghatak, U. R. Synthesis of condensed cyclic systems. II. Synthetic studies directed to substituted 1,2,3,3a,8,8a-hexahydrocyclopent[α]indene derivatives related to the degradation products of ryanodine. Indian J. Chem. 1969, 7, 215-223.
29. Cavalla, J. F.; Simpson, R.; White, A. C.; Substituted indeno[2,1-b]pyrroles as analgesic or antiinflammatory agents. US Patent 3,703,529, Nov 21, 1972; Chem. Abstr. 1973, 29619.
30. Snell, L. D.; Morter R. S.; Johnson K. M., Structural requirements for activation of the glycine receptor that modulates the N-methyl-D-aspartate operated ion channel. Eur. J. Pharmacol. 1988, 156, 105-110.